U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07315113) titled 'Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer' on Dec. 18, 2025.
Brief Summary: This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Study Start Date: Dec. 18, 2025
Study Type: INTERVENTIONAL
Condition:
EGFR Mutation Positive Non-small Cell Lung Cancer
EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
DRUG: NXP900
NXP900 is an orally administered inhibitor of SRC family kinases (SFK)
DRUG: Osimertinib
Osimertinib is an orally availab...